Khaitan Leena, Shea Brian J
Department of Surgery, University Hospitals Cleveland Medical Center, Cleveland, OH, USA.
Ann Transl Med. 2020 Mar;8(Suppl 1):S5. doi: 10.21037/atm.2020.01.89.
The laparoscopic vertical sleeve gastrectomy (LVSG) has become the most popular operation for the treatment of morbid obesity in the United States. Being a purely restrictive procedure, the LVSG works to reduce the caloric intake of patients as well as decrease appetite through removal of ghrelin producing cells. Initially developed as the first part of a combined two step restrictive and malabsorptive procedure, the LVSG developed as a standalone procedure when patients lost significant weight with the restrictive portion of the operation alone. Short term outcomes have been promising in terms of weight loss and resolution of comorbid conditions. Long term outcomes are still evolving, but do demonstrate durable weight loss for a significant number of patients. Concerns with the LVSG in the long term revolve around development or worsening of gastroesophageal reflux disease or weight regain. The LVSG has been demonstrated to be a useful tool in the surgical management of morbid obesity.
腹腔镜垂直袖状胃切除术(LVSG)已成为美国治疗病态肥胖最常用的手术。作为一种纯粹的限制性手术,LVSG通过切除产生胃饥饿素的细胞来减少患者的热量摄入并降低食欲。LVSG最初是作为联合两步限制性和吸收不良性手术的第一部分而开发的,当患者仅通过手术的限制性部分就减掉大量体重时,它发展成为一种独立的手术。短期结果在体重减轻和合并症的解决方面很有前景。长期结果仍在不断发展,但确实表明大量患者能持久减重。对LVSG的长期担忧主要围绕胃食管反流病的发展或恶化以及体重反弹。LVSG已被证明是病态肥胖手术治疗中的一种有用工具。